Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.61 |
| ▸ | NPC1 | O15118 | 6/20 | 0.61 |
| ▸ | CASP3 | P42574 | 1/20 | 0.59 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.59 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.59 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2270503 | 0.83 | NPC1 (0.59) | RAB9ANPC1CASP3SENP8SENP7 | |
| SCHEMBL12266910 | 0.82 | CSF1R (0.49) | RAB9ANPC1CASP3SENP8SENP7 | |
| SCHEMBL24307626 | 0.81 | NPC1 (0.58) | RAB9ANPC1CASP3SENP8SENP7 | |
| Ammonia Solution, Strong SCHEMBL28862474 | 0.81 | NPC1 (0.58) | RAB9ANPC1CASP3SENP8SENP7 | |
| SCHEMBL11786351 | 0.81 | CYP1A2 (0.51) | RAB9ANPC1CASP3SENP8SENP7 | |
| SCHEMBL1672 | 0.79 | PTPN1 (0.56) | RAB9ANPC1CASP3SENP8SENP7 | |
| SCHEMBL2272084 | 0.79 | CYP1A2 (0.54) | RAB9ANPC1CYP1A2CYP19A1CYP2C9 | |
| SCHEMBL16373702 | 0.79 | ALDH1A1 (0.58) | RAB9ANPC1ALDH1A1KDM4EUSP2 | |
| SCHEMBL13514282 | 0.79 | CYP1A2 (0.54) | RAB9ANPC1CASP3SENP8SENP7 | |
| SCHEMBL28746964 | 0.79 | CYP1A2 (0.54) | RAB9ANPC1CASP3SENP8SENP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105980387-B | Serine/threonine kinase inhibitor | 阵列生物制药公司 | 2019-04-19 | — | — | CN | claimed |
| EP-2401275-B1 | NAPHTHYRIDINE DERIVATIVES HAVING BRONCHODILATING ACTIVITY | RESPIRATORIUS AB (SE) | 2013-07-24 | — | — | EP | claimed |
| EP-1506175-B1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDGF RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-01 | — | — | EP | claimed |
| WO-2007001335-A2 | RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2007-01-04 | — | — | WO | claimed |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. (US) | 2006-09-21 | — | — | US | claimed |
| EP-1506175-A1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDGF RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-16 | — | — | EP | claimed |
| US-20040082639-A1 | N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-04-29 | — | — | US | claimed |
| WO-2003097609-A1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDFG RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-11-27 | — | — | WO | claimed |
| WO-2024107658-A2 | INHIBITORS OF TYK2 | VYRNWY THERAPEUTICS, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| CN-117126118-A | Synthesis method of celecoxib | 上海应用技术大学 | 2023-11-28 | — | — | CN | disclosed |
| US-11771738-B2 | Endoparasitic depsipeptides | ZOETIS SERVICES LLC (US) | 2023-10-03 | — | — | US | disclosed |
| WO-2023067322-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2023-04-27 | — | — | WO | disclosed |
| US-20230052191-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2023-02-16 | — | — | US | disclosed |
| CN-110483430-B | Preparation method of isoxazole derivative | 上海应用技术大学 | 2023-02-10 | — | — | CN | disclosed |
| EP-0192931-B1 | PROCESS FOR THE PREPARATION OF ISOXAZOLES | FIRMENICH SA (CH) | 1988-09-07 | — | — | EP | disclosed |
| US-4670109-A | ANODIC OXIDATION OF ALPHA-BETA UNSATURATED OXIMES | FIRMENICH SA (CH) | 1987-06-02 | — | — | US | disclosed |
| EP-0220947-A2 | Polyfluoroalkylisoxazolylamines, their preparation and use | SHIONOGI & CO., LTD. (JP) | 1987-05-06 | — | — | EP | disclosed |
| EP-0192931-A1 | Process for the preparation of isoxazoles | FIRMENICH SA (CH) | 1986-09-03 | — | — | EP | disclosed |
| US-4010193-A | (ALKYLAMINO)ALKYL SUBSTITUTED BENZOATES, LOCAL ANESTHETIC, ANTIFIBRILLATORY, ANTIARRHYTHMIAL | CHINOIN GYOGYSZER-ES VEGYESZETI TERMEKEK GYARA RT (HU) | 1977-03-01 | — | — | US | disclosed |
| US-3935219-A | Antimicrobial dihalonitromethylisoxazoles | PURDUE RESEARCH LABORATORY (US) | 1976-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11771738-B2 | Endoparasitic depsipeptides | VIP, PREP, VIPR1 | RAB9A 901/4885NPC1 1035/4885CASP3 1558/4885 |
| US-20040082639-A1 | N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | PDGFRA, PDGFRB, PDGFA | RAB9A 3338/4885NPC1 2618/4885CASP3 788/4885 |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | CLSPN, LMAN2, RPN2 | RAB9A 20/4885NPC1 4197/4885CASP3 2634/4885 |
| US-20230052191-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | RAB9A 480/4885NPC1 2546/4885CASP3 2777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.